Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
PYPD
PolyPid Ltd.
CAPPED RATING
PolyPid Ltd. (PYPD) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (F). The rating has held at C- for 2 weeks.
Quantitative Factor Evaluation • Updated
Overall Rating
2.1
/ 5.0
C-
Value
C+
Factor Score
2.5
/ 5.0
Growth
F
Factor Score
0.5
/ 5.0
Profitability
D
Factor Score
1.3
/ 5.0
Momentum
B+
Factor Score
3.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-6.5
EV / EBITDA
-4.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
31.2%
Price Return 12M
66.9%
Catalyst Signal
0.00
Market Cap
$127.2M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-243.6%
Historical Factor Score Progression
Held C- for 2 weeks
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | F (0.5) | D (1.3) | B+ (3.7) | C+ (2.6) | C- (2.1) |
| 2026-11-07 | C+ (2.5) | F (0.3) | D (1.3) | B+ (3.7) | C+ (2.7) | C- (2.1) |
| 2026-10-31 | C+ (2.5) | F (0.3) | D (1.4) | B+ (3.8) | C+ (2.7) | C- (2.1) |
| 2026-10-24 | C+ (2.5) | F (0.7) | D (1.3) | B+ (3.7) | C+ (2.6) | C (2.2) |
| 2026-10-17 | C+ (2.5) | F (0.7) | D (1.3) | C+ (2.8) | C+ (2.6) | C- (2.0) |
Page
1
of
4